How to Get a Zepbound Prescription in Canada (2026)

Zepbound's Health Canada indication expressly includes "chronic weight management" — with eligibility criteria written into the monograph in numbers you can read before you ever speak to a practitioner. That puts Zepbound in the same on-label position as Wegovy, and in a different position from Mounjaro, whose own tirzepatide monograph is authorized only for type 2 diabetes.

So the friction here isn't "will a prescriber consider this at all?" — it's two narrower questions:

1. Do I meet the criteria as written? They are specific: BMI thresholds, and at the lower one, a weight-related comorbidity.
2. Who pays? Drug plans generally treat weight-management medications very differently from diabetes medications — meeting the clinical criteria is not the same as being covered for the cost.

This guide follows that order: criteria, routes, then coverage.

The criteria below are quoted directly from the Health Canada authorized product monograph. Meeting them on paper is not the same as being prescribed — a practitioner assesses your full history — but they tell you what the conversation is anchored to.

"ZEPBOUND (tirzepatide injection) is indicated for once-weekly administration for chronic weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity, in adults with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity) or 27 kg/m2 to less than 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, prediabetes, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease)."

The same section sets out two Limitations of Use:

"ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products (e.g., Mounjaro®) or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended."

"The safety and efficacy of ZEPBOUND in combination with other products intended for weight management, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established."

That first Limitation matters for this specific guide: Zepbound and Mounjaro are the same active ingredient, tirzepatide, from the same manufacturer, Eli Lilly — a fact that shows up again below in how one telehealth provider prices the two together. On pediatrics, the monograph states plainly: "No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use."

If you are currently taking Mounjaro, another tirzepatide product, or any other GLP-1 receptor agonist, say so on your intake.

Your family doctor. Well placed to document what the criteria require — measured height and weight rather than self-reported, plus any comorbidity already in your chart. That documentation matters later, at the coverage stage. Slowest to start, strongest on follow-up.

A walk-in clinic. Faster to reach a clinician, weaker on records. A walk-in can measure you, but won't have your history of prior treatments — exactly what a private insurer tends to ask about when reviewing a claim.

Telehealth. Structured intake suits an indication with numeric criteria, and it's a practical route if you have no regular provider. Check three things before you pay: whether measurements are self-reported or verified, who manages the dose-escalation schedule and follow-up, and whether fees recur. Providers vary considerably — rather than take one provider's marketing at face value, compare telehealth providers on our hub.

Here Zepbound differs from Ozempic, Wegovy, and generic semaglutide on this site, and matches Mounjaro: Felix, the telehealth platform we earn a commission from, carries Zepbound directly. There's no redirect to a different drug. Felix's own pricing table doesn't list Zepbound as a separate row, though — it prices both Lilly tirzepatide brands together under one combined "Mounjaro/Zepbound" line, reflecting that they're the same manufacturer, same molecule, and same Patient Support Program. That combined line's monthly price starts at the 2.5 mg dose, is lower with Eli Lilly's Patient Support Program applied, and rises at higher maintenance doses; see our Felix Health review for its current price by dose. The initial assessment fee is $0. Approval is not guaranteed, and Felix does not operate in every province — confirm yours is one before you pay.

Before you decide, read our full Felix Health review — the current combined Mounjaro/Zepbound price table and how the manufacturer savings program affects it.

If cost is the deciding factor and Zepbound itself isn't a requirement, it's worth knowing what else is available through the same intake. Apo-semaglutide — Health Canada's generic version of Ozempic — is a different medication, not a substitute for Zepbound, but it's priced at a flat $149/month at the 0.25, 0.5 and 1.0 mg pen strengths through Felix, off-label for weight management. Whether either drug is appropriate for you is a question for a licensed practitioner, not a price comparison. Compare all telehealth providers on our hub rather than treating Felix as your only option.

A pharmacist. Scope is the constraint here, and it is sharply uneven. The Canadian Pharmacists Association's national chart shows Alberta as the only jurisdiction where independent pharmacist prescribing for any Schedule I drug is implemented — every other province and territory is marked not implemented. Renewing or extending an existing prescription is implemented everywhere except Nunavut, and adapting a dose, formulation, or regimen everywhere except the Northwest Territories and Nunavut (CPhA).

Outside Alberta, then, expect a pharmacist to maintain or adapt an existing Zepbound prescription rather than start one. Within Alberta the authority on the books isn't a blanket one either: it belongs to pharmacists who hold Additional Prescribing Authorization (APA), a credential layered on top of a standard pharmacy licence, not automatic for every pharmacist in the province. Whether an APA-holding pharmacist exercises it for a given medication is still their own clinical judgment and practice setting — worth asking locally rather than inferring from a scope chart.

1. Intake. Expect height, weight, and BMI to be captured explicitly, alongside medical history, current medications, allergies, and any weight-related conditions such as hypertension, prediabetes, or sleep apnea. Report accurately — an inaccurate intake produces an assessment that isn't about you.
2. Practitioner review. Asynchronous means a licensed practitioner reviews your written submission on their own schedule with no live conversation; synchronous means a scheduled video or phone consult. Given a dose-escalation schedule, it's reasonable to want a live conversation — check which model applies before paying.
3. The decision. A practitioner may approve, decline, ask for measurements or records, or suggest another approach. Meeting the BMI threshold is one input among several and does not entitle you to a prescription — and paying an assessment fee never guarantees an outcome.
4. Prescription and fill. If issued, it goes to the pharmacy you nominate, or to a partner or mail-order pharmacy.
5. Follow-up and coverage paperwork. Two things run in parallel: the dose-escalation schedule, and — if you're claiming against a private plan — any prior authorization forms your insurer requires. Find out who completes them; it's a common stall point.

We don't publish "prescription in X hours" claims. Those numbers come from provider marketing and we have not verified any of them.

A valid Zepbound prescription can generally be filled at any licensed Canadian pharmacy — chains, independents, or mail-order. Pharmacies set their own cash prices, and the spread between them for an identical pen is often wider than people expect, which is the entire reason this site exists.

Across 6 Canadian pharmacies, Zepbound runs $276–$599 per pen (updated October 8, 2026).

Current pharmacy-by-pharmacy listings live on the Zepbound drug page. No generic version of tirzepatide is approved in Canada — see our generic Zepbound status guide for the current patent timeline and how that mechanism would work if it ever changes. How we collect and verify these numbers is documented on our methodology page.

Coverage is the defining issue for Zepbound, the same way it is for Wegovy. The CMA notes that GLP-1 drugs are usually covered when prescribed for type 2 diabetes, but that "coverage looks very different for weight management; only a small number of private insurance plans offer partial coverage for GLP-1 drugs approved for chronic weight management, and public drug plans generally do not cover them" (CMA).

Being on-label doesn't translate into being publicly funded here; the CMA observes that when insurance doesn't cover a GLP-1-class drug, many Canadians pay out of pocket. Check your private plan's wording for weight-management drugs before you start, and expect prior authorization rather than automatic approval where any coverage exists.

Not having a family doctor is common enough to be the norm for millions of people, and it doesn't disqualify you from care. An estimated 5.9 million adults in Canada do not have a family doctor, nurse practitioner, or primary care team they see regularly, per the OurCare survey led by Dr. Tara Kiran at Unity Health Toronto with the Canadian Medical Association (CMA, December 8, 2025).

For Zepbound specifically, the gap creates a documentation problem more than an access problem. The criteria reference an initial BMI and, at the lower threshold, a weight-related comorbidity — usually established through prior measurements and labs kept in a chart that, without a regular provider, may not exist in one place. Gather what you can before an intake: recent bloodwork, blood pressure readings, prior diagnoses, and your pharmacy's medication history. It makes the assessment more accurate and any insurance paperwork easier.

We've written a full guide to this specific problem: how to get a GLP-1 prescription in Canada without a family doctor — walk-in clinics, telehealth, pharmacist prescribing by province, and what changes at renewal.

Any site offering Zepbound without a prescription is a red flag. The CMA states it directly: if a website says you can get a GLP-1 drug without a prescription, that's a major red flag (CMA).

Health Canada lists warning signs that an online pharmacy may be fraudulent, including that it "Does not require a valid prescription," offers drugs that claim to have a "miracle cure" for serious conditions, offers drugs at very low discounted prices, does not provide a "bricks and mortar" business address, or is located outside of Canada. A legitimate one, by contrast, "Requires a valid prescription from a physician or other health practitioner licensed to practice in Canada," is licensed by a provincial or territorial pharmacy regulatory authority, has a Canadian-licensed pharmacist available to answer questions, and provides a street address located in Canada (Health Canada, Choosing a safe online pharmacy).

Health Canada further warns that buying from a fraudulent online pharmacy means "You may end up with a drug that contains wrong or harmful ingredients, or no medicinal ingredients at all," and that medications requiring refrigeration "may not be stored or transported properly" — relevant for any injectable. On importation: "You cannot legally import a prescription drug unless you are a practitioner, a drug manufacturer, a wholesale druggist, a registered pharmacist, or a resident of a foreign country while a visitor in Canada."

Because coverage for weight-management drugs is limited, cost pressure is real — and that pressure is exactly what unauthorized sellers target. A price far below what licensed Canadian pharmacies charge is a warning sign, not a bargain.